Recardio
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
201 Mission St, San Francisco, Californi...Website
www.recardio.euRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Recardio
Recardio is a late clinical-stage life science company based in San Francisco, California, specializing in regenerative cardiac medicine for cardiovascular and other diseases. The company is focused on developing breakthrough therapies, including its lead drug candidate, dutogliptin, which activates cardiac regeneration and healing. Recardio is engaged in clinical evaluations and has initiated collaborations with pharmaceutical leaders to enhance its product development. The company aims to leverage technology and innovative approaches to improve patient outcomes in cardiovascular care.Explore more
Recardio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Recardio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Recardio launches new products
Check out if Recardio is spiking on competitors!
Earning: See what the market has to say on Recardio recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Recardio
Click to see if Recardio had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Recardio has new funding data
Recardio, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Recardio has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Recardio
Compare insights from companies similar to Recardio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Recardio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Recardio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Recardio.
Recardio financials insights
Gather financial insights about Recardio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$11M
Recardio Tech Stack
A closer look at the technologies used by Recardio
Recardio News & Media
Recardio's Positive Phase 2 Results Presented as Latebreaker at World Congress on Acute Heart Failure 2022 in Madrid
Recardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the positive study results of Recardio's Phase 2 clinical study in Acute Myocardial Infarction were presented on Saturday, May 21, 2022, during the Latebreaker Session at the World Congress on Acute Heart Failure 2022 in Madrid.Recardio's Phase 2 Results Will Be Presented as Latebreaker at World Congress on Heart Failure 2022 in Madrid
Recardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the study results of Recardio's Phase 2 clinical study in Acute Myocardial Infarction will be presented on Saturday, May 21, 2022, during the Latebreaker Session at the World Congress on Acute Heart Failure 2022 in Madrid.Recardio Completes Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin
Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, announced the completion of its Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction.Interim Analysis of Recardio's Phase II Clinical Trial Published in European Heart Journal
Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its positive results of the interim analysis of Recardio's Phase II clinical trial in AMI were published in the latest release of the European Heart Journal. The current version of the journal relates to the presentation during the 2020 Congress of the European Society of Cardiology.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Recardio
Sign Up For FreeTo access detailed company insights
Recardio is a late clinical-stage life science company based in San Francisco, California, specializing in regenerative cardiac medicine for cardiovascular and other diseases. The company is focused on developing breakthrough therapies, including its lead drug candidate, dutogliptin, which activates cardiac regeneration and healing. Recardio is eng... Read More
